IR Style Guide

News & Events

Corporate Presentation
Corporate Presentation - October 2019
News Releases

Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

December 6, 2019

NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial Officer.

Additional Formats
PDF Version

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

December 6, 2019

NEW YORK , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral

Additional Formats
PDF Version

Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

November 29, 2019

NEW YORK , Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’s 31 st

Additional Formats
PDF Version

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

November 7, 2019

Net revenue for ELZONRIS ® was $13.3 million for the third quarter New patient starts estimated to have increased greater than 20% from last quarter Conference call and live webcast scheduled for tomorrow, Friday November 8 th , at 8:00 AM ET NEW YORK , Nov.

Additional Formats
PDF Version

Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

November 6, 2019

NEW YORK , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp; SL-401), a novel targeted therapeutic

Additional Formats
PDF Version

Upcoming Events
More events are coming soon.
Past Events